<DOC>
	<DOCNO>NCT00038831</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose Mylotarg combine chemotherapy patient receive allogeneic bone marrow transplantation . Researchers study effect treatment combination patient high-risk acute leukemia , chronic myelogenous leukemia , myelodysplastic syndrome . Primary Objective : 1 . To determine safety maximum tolerate dose Mylotarg part reduced-intensity preparative regimen patient undergo related , mismatched-related match unrelated donor transplantation . Secondary Objectives : 1 . To evaluate response rate , engraftment kinetics degree chimerism achievable strategy . 2 . To evaluate incidence severity GVHD population 3 . To evaluate disease-free overall survival relapse rate .</brief_summary>
	<brief_title>Allo Transplantation With Mylotarg , Fludarabine Melphalan AML , CML MDS</brief_title>
	<detailed_description>Before treatment start , patient complete physical exam , include blood urine test . Patients chest x-ray , heart scan , lung function test , bone marrow biopsy . Women able child pregnancy test . In study , patient receive Mylotarg twelve day transplant . The first patient receive Mylotarg low dose level . As study continue , dose level increase long severe side effect occur . Mylotarg may give outpatient Ambulatory Treatment Center ( ATC ) . Patients monitor ATC eight hour day infusion . For next 5 day , patient evaluate Clinic daily basis per physician order . One week transplant , patient admit hospital continue treatment inpatient . Patients experience side effect leukemia leukemia treatment may need hospitalize earlier . On 1st day hospitalization , patient receive fluid vein . On 5th , 4th , 3rd 2nd day transplant , patient receive Fludarabine , vein . Melphalan give vein 2nd day transplant . Patients receive five six antigen match unrelated bone marrow also receive antithymocyte globulin , vein , 3rd , 2nd 1st day transplant . On 7th day , healthy blood stem cell bone marrow donor give central catheter . Some donor bone marrow stem cell may save future therapy . Patients also receive several medication help treatment work help prevent infection immune system weak . Tacrolimus methotrexate give prevent graft-versus-host disease ( GVHD ) . GVHD occur donor 's immune cell fight patient 's body . The Tacrolimus start day transplant continue six month . Tacrolimus give vein first mouth patient able eat . Methotrexate give vein day 1 , 3 , 6 possibly day 11 transplant . Sulfamethoxazole ( Bactrim ) pentamidine give fight bacteria . Bactrim give mouth count good . Pentamidine give vein count low . Acyclovir give first vein Valtrex give pill prevent viral infection . Granulocyte colony-stimulating factor ( G-CSF ) give help new bone marrow grow . It give injection skin begin 7th day transplant . It continue patient 's white blood cell reach acceptable level . Overall , drug give long 6 month possibly longer . Other medication may necessary . If allergic drug , change make . Patients hospital 3-4 week . Patients checkups every day discharge hospital 3 time week blood count improve . Patients see doctor least every week 100 day bone marrow transplant . Patients must stay Houston time . After 100 day , patient return least every 3 month first year , every 6 month additional two year . Bone marrow sample take 1 month , 3 month , 6 12 month transplant . This investigational study . All drug study approve FDA . About 47 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients 1275 year age Patients eligible deem ineligible conventional high dose chemotherapy program concurrent medical condition . Patients refractory AML always eligible ejection fraction &gt; 35 , FEV1 , FVC , DLCO &gt; 40 % , abnormal LFT 's . Patients must recover previous Grade IIIIV toxicity due prior antineoplastic therapy ( except alopecia ) . Patients follow disease category eligible : 1 . AML induction failure , relapse 2nd remission 2 . MDS IPI INT2 Highrisk disease ( Appendix 4 ) CMML 3 . CML accelerate phase blast crisis 4 . Interferon STI resistant CML eligible conventional stem cell transplant Patients receive prior BMT eligible . If myeloablative chemoradiotherapy use prior transplant patient must &gt; 90 day transplant . If nonmyeloablative therapy use patient must &gt; 30 day posttransplant . Leukemia cell must express cell surface CD33 evaluate flow cytometry &gt; 20 % leukemia cell . Patients must HLAcompatible related donor ( 6/6 5/6 HLAmatch ) capable donate bone marrow GCSF stimulate peripheral blood stem cell use aphereses technique 6/6 HLA match unrelated bone marrow donor ( serologic match Class I , molecular match DR ? 1 ) . Patients must ECOG PS &lt; 2 ( Appendix 6 ) , Cr &lt; 2.0 , bilirubin &lt; 2 , ( SGPT ) &lt; 3x normal Patients must estimate life expectancy &gt; 3 month Patient donor must sign informed consent . Unrelated donor consent accord National Donor Marrow Registry policy uncontrolled active infection HIV disease pregnancy nurse active , uncontrolled CNS leukemia</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Acute Myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Mylotarg</keyword>
	<keyword>Gemtuzumab</keyword>
	<keyword>Gemtuzumab ozogamicin</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Anti-thymocyte globulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Allogeneic Bone Marrow</keyword>
	<keyword>Peripheral Blood Stem Cell Transplantation</keyword>
	<keyword>Allo PBSCT</keyword>
	<keyword>Allogeneic transplantation</keyword>
</DOC>